Bayer, Germany, acquired Yunnan Hong pharmaceutical industry as a whole with 3.6 billion yuan

The reporter recently learned from the Management Committee of Kunming high tech Zone that Kunming Dianhong Pharmaceutical Group Co., Ltd., a well-known enterprise in the zone, has successfully signed an equity transfer agreement with Bayer, an international pharmaceutical giant Bayer of Germany will purchase all shares of Dianhong Pharmaceutical Co., Ltd at a price of 3.6 billion yuan As a Chinese native medicine and health care company rooted in the national biological industry base of Kunming high tech Zone, Dianhong pharmaceutical has become a well-known domestic enterprise providing innovative and effective chemicals and traditional Chinese medicine in many fields such as dermatitis, acne, recurrent oral ulcer, hyperosteogeny and endometriosis after years of development Its "Kangwang" series products are produced in China It enjoys a high reputation Its achievements in the development of OTC and TCM have attracted the continuous attention of multinational pharmaceutical giants including Bayer Internationalization is the only way for Yunnan's bio industry to become bigger and stronger It is also an important goal for the development of National Bio Industry Base of Kunming high tech Zone Bayer's merger and acquisition of Dian Hong pharmaceutical industry is conducive to creating more opportunities for its products to go to the world by virtue of Bayer's advantages in marketing, product manufacturing and R & D, which will greatly improve the international knowledge of Yunnan pharmaceutical industry Mingdu is a great demonstration for other enterprises in Kunming National biological industry base to follow the international road and make some characteristic and advantageous varieties of Yunyao go to the world The success of Bayer and Dianhong indicates that the internationalization of the national biological industry base of Kunming high tech Zone has reached a new level.